Phio Pharmaceuticals Corp. Profile Avatar - Palmy Investing

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates…

Biotechnology
US, Marlborough [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Phio Pharmaceuticals Corp. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of PHIO's Analysis
CIK: 1533040 CUSIP: 71880W303 ISIN: US71880W4024 LEI: - UEI: -
Secondary Listings
PHIO has no secondary listings inside our databases.